Sign inJoin waitlistJoin the waitlist

Abinhav Deol

Physician · Barbara Ann Karmanos Cancer Institute - Detroit

Credentials: · · · ·

History

Barbara Ann Karmanos Cancer Institute - Detroit
2021–Present

Hematology and Medical Oncology
2003–2006
Internal Medicine
2000–2003
Doctor of Medicine
1996–2000

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
The Lancet Oncology · 2019 · 1,921 citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a…
The Lancet · 2021 · 1,514 citations

Joseph Uberti
46 papers
Lois Ayash
38 papers
VR
Voravit Ratanatharathorn
38 papers
Lawrence Lum
24 papers
DM
Dipenkumar Modi
21 papers · 8 as a fellow
Zaid Al-Kadhimi
15 papers
Asif Alavi
14 papers
Olalekan Oluwole
14 papers
YL
Yi Lin
14 papers
JM
Javier Munoz
12 papers
Andre Goy
11 papers
David Miklos
10 papers

Clinical trials

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Principal investigator · Completed · Phase 2
Barbara Ann Karmanos Cancer Institute
2018–2022
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Principal investigator · Terminated · Phase 1
Barbara Ann Karmanos Cancer Institute
2015–2018
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Principal investigator · Terminated · Phase 1
Barbara Ann Karmanos Cancer Institute
2012–2018
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
Principal investigator · Terminated · Phase 2
Barbara Ann Karmanos Cancer Institute
2010–2019